Literature DB >> 9392835

Enterostatin actions in the amygdala and PVN to suppress feeding in the rat.

L Lin1, D A York.   

Abstract

The pentapeptide enterostatin (ENT) inhibits feeding after injection into the cerebral ventricles. To localize the central sites of action of ENT, the peptide (0.01 to 3.3 nM) was microinjected into several brain regions and the intake of a high fat diet was measured. The results show that ENT injection in the paraventricular nucleus (PVN) or the amygdala (AMYG) produced a bi-phasic dose related feeding response, low doses of ENT inhibited feeding while higher dose had no effect. The effective dose to inhibit feeding in the AMYG was 10 fold lower than that in the PVN. No changes in food intake were observed after ENT injection into the ventromedial hypothalamus and nucleus tractus solitarius. The data provide further support that there are targets in the CNS for ENT and suggest that central ENT function is site specific.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392835     DOI: 10.1016/s0196-9781(97)00191-5

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

1.  Enterostatin inhibition of dietary fat intake is modulated through the melanocortin system.

Authors:  Ling Lin; Miejung Park; David A York
Journal:  Peptides       Date:  2006-11-17       Impact factor: 3.750

2.  5-HT1B receptors modulate the feeding inhibitory effects of enterostatin.

Authors:  Ling Lin; David A York
Journal:  Brain Res       Date:  2005-10-26       Impact factor: 3.252

3.  Different metabolic responses to central and peripheral injection of enterostatin.

Authors:  Ling Lin; Miejung Park; Matt Hulver; David A York
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-12-08       Impact factor: 3.619

4.  Enterostatin deficiency increases serum cholesterol but does not influence growth and food intake in mice.

Authors:  Rita Miller; Dymphna D'Agostino; Charlotte Erlanson-Albertsson; Mark E Lowe
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-21       Impact factor: 4.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.